Indeed. Despite my criticisms I don't find the outcome "tailored boosters not any better than vanilla boosters" implausible. Which means, infection efficacy will be fleeting, judging by the situation in Israel (0 infection efficacy in the under 60s for either triple-dosed or double-dosed)
Indeed. Despite my criticisms I don't find the outcome "tailored boosters not any better than vanilla boosters" implausible. Which means, infection efficacy will be fleeting, judging by the situation in Israel (0 infection efficacy in the under 60s for either triple-dosed or double-dosed)
Indeed. Despite my criticisms I don't find the outcome "tailored boosters not any better than vanilla boosters" implausible. Which means, infection efficacy will be fleeting, judging by the situation in Israel (0 infection efficacy in the under 60s for either triple-dosed or double-dosed)